GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Steris PLC (NYSE:STE) » Definitions » Return-on-Tangible-Equity

STE (Steris) Return-on-Tangible-Equity : 105.73% (As of Mar. 2025)


View and export this data going back to 1992. Start your Free Trial

What is Steris Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Steris's annualized net income for the quarter that ended in Mar. 2025 was $583 Mil. Steris's average shareholder tangible equity for the quarter that ended in Mar. 2025 was $551 Mil. Therefore, Steris's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 was 105.73%.

The historical rank and industry rank for Steris's Return-on-Tangible-Equity or its related term are showing as below:

STE' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 111.07   Med: 180.5   Max: 324.04
Current: 161.61

During the past 13 years, Steris's highest Return-on-Tangible-Equity was 324.04%. The lowest was 111.07%. And the median was 180.50%.

STE's Return-on-Tangible-Equity is ranked better than
94.59% of 758 companies
in the Medical Devices & Instruments industry
Industry Median: 2.605 vs STE: 161.61

Steris Return-on-Tangible-Equity Historical Data

The historical data trend for Steris's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Steris Return-on-Tangible-Equity Chart

Steris Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 180.50 Negative Tangible Equity Negative Tangible Equity 324.04 160.58

Steris Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 322.20 174.65 156.47 105.73

Competitive Comparison of Steris's Return-on-Tangible-Equity

For the Medical Devices subindustry, Steris's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Steris's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Steris's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Steris's Return-on-Tangible-Equity falls into.


;
;

Steris Return-on-Tangible-Equity Calculation

Steris's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=614.641/( (112.17+653.337 )/ 2 )
=614.641/382.7535
=160.58 %

Steris's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=582.688/( (448.883+653.337)/ 2 )
=582.688/551.11
=105.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Steris  (NYSE:STE) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Steris Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Steris's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Steris Business Description

Traded in Other Exchanges
Address
5960 Heisley Road, Mentor, OH, USA, 44060
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
Executives
Cary L Majors officer: VP, N America Com Operations 5960 HEISLEY ROAD, MENTOR OH 44060
Michael J Tokich director, officer: Sr. Vice Pres., CFO C/O STERIS CORP, 5960 HEISLEY RD, MENTOR OH 44060
Christopher S Holland director ARAMARK CORP, 1101 MARKET ST 29TH FLOOR, PHILADELPHIA PA 19107
Julia Madsen officer: Senior VP, Life Sciences 5960 HEISLEY ROAD, MENTOR OH 44060
Renato Tamaro officer: V.P. & Corporate Treasurer 5960 HEISLEY ROAD, MENTOR OH 44060
Cynthia L Feldmann director 17 WINTHROP ROAD, WAYLAND MA 01778
Mohsen Sohi director C/O STERIS CORPORATION, 5960 HEISLEY ROAD, MENTOR OH 44060
Karen L Burton officer: VP, Controller & CAO 5960 HEISLEY ROAD, MENTOR OH 44060
Jacqueline B Kosecoff director 5960 HEISLEY ROAD, MENTOR OH 44060
Richard C Breeden director 100 SOUTH WACKER, SUITE 1800, CHICAGO IL 60606
Esther M. Alegria director 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
John Adam Zangerle director, officer: Sr. VP, Gen Counsel, and Sec. 5960 HEISLEY ROAD, MENTOR OH 44060
Andrew Xilas officer: SVP and GM, Dental 5960 HEISLEY ROAD, MENTOR OH 44060
Paul Edward Martin director C/O UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
David B Lewis director